Organon plans to acquire Dermavant and its novel topical treatment, Vtama® (tapinarof) cream, 1%. Organon has agreed to acquire Dermavant for aggregate consideration of up to approximately $1.2 billion, with an upfront payment of $175 million and a $75 million milestone payment upon regulatory approval in AD. Additional payments of up to $950 million will be made for the achievements of certain commercial milestones.
Vtama, an aryl hydrocarbon receptor agonist, is indicated for the topical treatment of plaque psoriasis in adults in the US.
The FDA is reviewing a Supplemental New Drug Application (sNDA) for VTAMA cream as a potential treatment for atopic dermatitis (AD) in adults and children two years of age and older, with Prescription Drug User Fee Act (“PDUFA”) action expected in the fourth quarter of calendar year 2024.
Dermavant, a Roivant Company, owns the rights to Vtama cream globally excluding China and has out licensed Japan rights. The deal is expected to close in the fourth quarter of this year.
The post Organon to Acquire Dermavant appeared first on Dermatology Education Foundation.